Navigation Links
Endo Pharmaceuticals Announces Proposal to Change Name of Parent Company and Rebrands Enterprise: Revealing an Innovative Corporate Structure Dedicated to Redefining Healthcare Value
Date:3/1/2012

ns forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements.  Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in our Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

THE ADOPTION OF THIS NAME IS SUBJECT TO SHAREHOLDER APPROVAL.

WE ARE NOT SOLICITING AND WILL NOT ACCEPT ANY PROXIES AT THIS TIME, BUT WILL DO SO IN THE ORDINARY COURSE OF HOLDING OUR ANNUAL MEETING IN MAY. WE URGE ALL SHAREHOLDERS TO READ OUR PROXY STATEMENT BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSAL. OUR PROXY MATERIALS WILL BE AVAILABLE TO SHAREHOLDERS FREE OF CHARGE FROM US IN APRIL 2012 AND AT THE SECURITIES AND EXCHANGE COMMISSION'S (SEC) WEBSITE.


'/>"/>
SOURCE Endo Pharmaceuticals Holdings Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Array BioPharma Inc. (NASDAQ: ARRY ) today ... year of its fiscal year ended June 30, ... Array, noted, "Binimetinib and encorafenib, two innovative oncology ... regulatory submissions in 2016. Additional data shared over ... cancer further validate the value of these programs ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
(Date:8/3/2015)... , Aug. 3, 2015  EnteroMedics Inc. (NASDAQ: ETRM ... to treat obesity, metabolic diseases and other gastrointestinal disorders, ... been appointed to the Board of Directors, effective July ... II Director until the 2018 annual meeting or until ... McDougal has served in an executive capacity in the ...
Breaking Medicine Technology:Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3
... Pfizer (NYSE: PFE ) today ... Inc., a privately held drug discovery and clinical development ... a wholly owned subsidiary of Pfizer Inc.   ... Pfizer Inc: Working together for a healthier ...
... Baxano, Inc. ( www.baxano.com ) today announced that two of ... Spine Care at the 2010 Spine Technology Awards. The iO-Flex™ ... in the Best New Technology in Lumbar Care. ... Technology Awards Gala in Orlando, FL. Baxano, Inc. was awarded ...
Cached Medicine Technology:Baxano, Inc. Awarded Prestigious 2010 Spine Technology Awards 2
(Date:8/3/2015)... ... August 03, 2015 , ... As reported in ... Lifetime reality series, “Atlanta Plastic” is getting attention for moving outside traditional ethnic ... its predominantly African-American cast of doctors and patients. Beverly Hills based plastic surgeon ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to ... related claims in which a claimant alleged to have suffered an arterial blood clot ... birth control pills, Yaz, Yasmin and Ocella, has been ongoing for well-over five years. ...
(Date:8/3/2015)... ... August 03, 2015 , ... Pitt Researchers to Monitor ... of Pittsburgh School of Medicine are leading a five-year, $5 million initiative to ... , A cooperative agreement awarded by the U.S. Agency for International Development ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... notes that while an overwhelming number of Hispanics believe people can positively ... overwhelming 70 percent of participants queried said making diet changes was important. Far ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Dental practice ... help patients in need. Most people know that general health emergencies, such as broken ... fewer amount of people know where to turn to during a dental emergency. This ...
Breaking Medicine News(10 mins):Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 2Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 3Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3
... Meeting on Lessons from 2004 Tsunami, WASHINGTON, ... psychosocial support responders are meeting to,discuss how disasters ... operations in response to the 2004 tsunami. The ... the American Red Cross. The,American Red Cross oversees ...
... 360m Collaboration with Harvard Medical International Provides ... and Vital Global Health Information, BALTIMORE, Jan. 29 ... the reach of their groundbreaking MEDEX,360m partnership with the ... business and leisure travelers., Like the original MEDEX ...
... 29 /PRNewswire/ - There is new hope for ... called DizzyFIX,patients with vertigo can now treat themselves. ... this visual device helps treat the most common,type ... DizzyFIX has received a number of medical ...
... but unless we harness the powers of our microbial co-habitants ... according to an article in the February 2008 issue of ... organisms that we are, it is easy to view this ... Reay from the University of Edinburgh. In truth of course, ...
... enterprise security, reduces risk and ... ... a global,provider of integrated security, risk and audit management solutions, ... National,Health Service (NHS) has selected its flagship SecureVue(R) platform to,proactively ...
... of Respondents Feel Their Overall Health Affects Their,Recovery ... Mental Health,America of San Diego today released ... overall healthcare in mental health settings from the,perspective ... that although both groups are aware of actions ...
Cached Medicine News:Health News:Global Experts Convene to Discuss Emotional Trauma Caused by Disasters 2Health News:MEDEX / Harvard Partnership Now Offers Affordable, New Intelligence to Individual Business & Leisure Travelers 2Health News:All Star Sales Introduces DizzyFIX a New Treatment for Vertigo and Dizziness 2Health News:The North Western Deanery of UK's National Health Service Selects eIQnetworks' SecureVue for Comprehensive IT Assurance 2Health News:The North Western Deanery of UK's National Health Service Selects eIQnetworks' SecureVue for Comprehensive IT Assurance 3Health News:First-of-Its-Kind National Online Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia 2Health News:First-of-Its-Kind National Online Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia 3Health News:First-of-Its-Kind National Online Survey Uncovers Obstacles to Comprehensive Healthcare for People With Schizophrenia 4
... The MaxxAir ETS™ is a therapeutic, ... of beds., ,INDICATIONS , Prevention ... who are difficult to turn, Large patients ... from a pressure relief surface, Patients whose ...
... full-featured healthcare bed system providing a comfortable, ... management of larger patients, ,INDICATIONS: ,Large ... patients at risk for pressure ulcers, ... lbs. (including accessories), ,PRECAUTION: ,Side Rails ...
... beds feature folding head end and foot end deck ... head end and foot end deck panels folded the ... 67". This compact length makes storage, delivery and pick ... is not available on Model 4748B, Basic Maxi Rest ...
... A single solution., ,Hill-Rom engineers designed ... safety where its needed. Its long list ... the caregiver and patient from injury, while ... like other TotalCare® beds, but its different ...
Medicine Products: